Market Cap 7.74B
Revenue (ttm) 1.02B
Net Income (ttm) 444.09M
EPS (ttm) N/A
PE Ratio 13.76
Forward PE 11.41
Profit Margin 43.74%
Debt to Equity Ratio 4.54
Volume 994,200
Avg Vol 2,059,548
Day's Range N/A - N/A
Shares Out 116.97M
Stochastic %K 42%
Beta 1.16
Analysts Sell
Price Target $75.56

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subc...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 794 8889
Fax: 858 704 8311
Address:
12390 El Camino Real, San Diego, United States
Sean29md
Sean29md Oct. 24 at 5:16 PM
$HALO Clearly, it was not the concern over earnings growth in 2030’s alone that’s been plaguing Halozyme with ridiculously low PE and PEG ratios. Investors reactions to both Evotec and Elektrofi M&A news show that there are significant other factors. Although Elektrofi is a far better fit for Halozyme and should at least partially address the earnings growth in 2030’s, the market reaction has been far more negative than a typical reaction to M&A news for the acquiring company. Yes the share price has gone up over the past several years (outperforming S&P and Nasdaq) but Halo’s EPS has far outgrown the share price so much so that Halozyme is not only far below its peers PE ratios, it also hovering near its own historical PE’s all time lows. The main reason behind this massive undervaluation is lack of storytelling. Strong CEO and C-suties tell a compelling story that attracts new investors. https://www.weforum.org/stories/2025/01/storytelling-key-to-success-in-the-disruption-era/
1 · Reply
ZacksResearch
ZacksResearch Oct. 23 at 4:06 PM
$HALO raises its 2025 outlook — but can partner royalties really power the next leg of growth? Revenue guidance is climbing on strong royalty momentum from Darzalex SC, Phesgo, and Vyvgart Hytrulo — yet dependence on partners still looms large. Full breakdown on what this means for Halozyme’s growth story 👉 https://www.zacks.com/stock/news/2775263/will-higher-royalties-from-partners-fuel-halos-growth-in-h2-2025?cid=sm-stocktwits-2-2775263-teaser-17308&ADID=SYND_STOCKTWITS_TWEET_2_2775263_TEASER_17308
0 · Reply
ZacksResearch
ZacksResearch Oct. 23 at 3:06 PM
$HALO's 37.6% rally YTD — examining its current valuation at this premium. 🚀 🔍 Revenue growth fueled by strong royalties from J&J's Darzalex SC, Roche's Phesgo, and argenx’s Vyvgart Hytrulo. 📈 EPS estimates for 2025 & 2026 are on the rise, but the stock trades at a pricey P/S ratio of 6.93 vs. the industry's 2.28. Discover if HALO's growth justifies its valuation here 👉 https://www.zacks.com/stock/news/2775263/will-higher-royalties-from-partners-fuel-halos-growth-in-h2-2025?cid=sm-stocktwits-2-2775263-body-17294&ADID=SYND_STOCKTWITS_TWEET_2_2775263_BODY_17294
0 · Reply
Sean29md
Sean29md Oct. 22 at 3:08 PM
$HALO markets will sniff out the new Enhanze deal (likely with Gilead). Don’t be surprised if halo share prices rise ahead of the official news. If it is indeed Gilead (based on the patent the two companies filed jointly), expect a minimum of 20-30% gains.
0 · Reply
Sean29md
Sean29md Oct. 21 at 4:23 PM
$HALO $GILD Halozyme's earnings release was supposed to be on 10/28. Now it's been moved back to 11/3 which is after Golead's 10/30 earnings call. Coincidence? The linked (see below) patent (WO2025188901) appears to describe the use of Halozyme's Enhanze drug delivery technology in combination with Trodelvy, which is a breast cancer therapy developed by Gilead[1]. The fact that Halozyme is filing intellectual property specifically covering the pairing of its Enhanze platform with a Gilead molecule strongly suggests ongoing technical collaboration, and is often a precursor to a formal commercial partnership or licensing agreement. The patent in question is a strong signal that Halozyme and Gilead are either in late-stage partnership discussions or at the threshold of a formal deal announcement covering Enhanze-enabled subcutaneous Trodelvy delivery. patentscope.wipo.int/search/en/deta…
0 · Reply
JarvisFlow
JarvisFlow Oct. 20 at 3:35 PM
Morgan Stanley has updated their rating for Halozyme Therapeutics ( $HALO ) to Overweight with a price target of 79.
1 · Reply
Sean29md
Sean29md Oct. 20 at 3:23 PM
$HALO Many thanks to Morgan Stanley for the opportunity to load up more one week ahead of earnings.
1 · Reply
Sean29md
Sean29md Oct. 20 at 2:33 PM
$HALO Many thanks to Morgan Stanley for the opportunity to load up more one week ahead of earnings.
0 · Reply
NoobyDoo
NoobyDoo Oct. 17 at 4:32 PM
$HALO Something big this way comes…Gilead partnership announcement soon? 🤔 I like our chances $HALO
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 3:39 PM
Enter: $HALO NOV 21 2025 $70 CALLS Buy in Price: $2.50 - $2.65 Take Profit: $3.55 Stop Bleeding: $2.20 ROI Potential: 42% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
Latest News on HALO
Halozyme Just Bought Its Next Decade Of Growth

Oct 23, 2025, 1:17 PM EDT - 2 days ago

Halozyme Just Bought Its Next Decade Of Growth


Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript

Oct 1, 2025, 3:22 PM EDT - 24 days ago

Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript


Identify Superstar Stocks Like Halozyme with Money Flows

Aug 29, 2025, 2:01 PM EDT - 2 months ago

Identify Superstar Stocks Like Halozyme with Money Flows


Halozyme to Participate at Upcoming Investor Conferences

Aug 28, 2025, 8:30 AM EDT - 2 months ago

Halozyme to Participate at Upcoming Investor Conferences


Halozyme Therapeutics Added to Russell 1000® Index

Jun 30, 2025, 4:05 PM EDT - 4 months ago

Halozyme Therapeutics Added to Russell 1000® Index


Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat

May 12, 2025, 10:44 AM EDT - 5 months ago

Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat


Halozyme Therapeutics: Still Undervalued Ahead Of Earnings

May 1, 2025, 9:06 AM EDT - 6 months ago

Halozyme Therapeutics: Still Undervalued Ahead Of Earnings


Halozyme Joins the $1 Billion Club

Mar 21, 2025, 7:35 AM EDT - 7 months ago

Halozyme Joins the $1 Billion Club


Halozyme: Recent Approvals Alter My Appetite

Dec 31, 2024, 2:41 AM EST - 10 months ago

Halozyme: Recent Approvals Alter My Appetite


Halozyme to Present at Upcoming Investor Conferences

Nov 27, 2024, 8:30 AM EST - 11 months ago

Halozyme to Present at Upcoming Investor Conferences


Halozyme withdraws $2.1 bln buyout offer for Evotec

Nov 22, 2024, 8:55 AM EST - 1 year ago

Halozyme withdraws $2.1 bln buyout offer for Evotec

EVO


Halozyme CEO: Evotec Is Poised for Growth

Nov 18, 2024, 4:00 PM EST - 1 year ago

Halozyme CEO: Evotec Is Poised for Growth

EVO


Sean29md
Sean29md Oct. 24 at 5:16 PM
$HALO Clearly, it was not the concern over earnings growth in 2030’s alone that’s been plaguing Halozyme with ridiculously low PE and PEG ratios. Investors reactions to both Evotec and Elektrofi M&A news show that there are significant other factors. Although Elektrofi is a far better fit for Halozyme and should at least partially address the earnings growth in 2030’s, the market reaction has been far more negative than a typical reaction to M&A news for the acquiring company. Yes the share price has gone up over the past several years (outperforming S&P and Nasdaq) but Halo’s EPS has far outgrown the share price so much so that Halozyme is not only far below its peers PE ratios, it also hovering near its own historical PE’s all time lows. The main reason behind this massive undervaluation is lack of storytelling. Strong CEO and C-suties tell a compelling story that attracts new investors. https://www.weforum.org/stories/2025/01/storytelling-key-to-success-in-the-disruption-era/
1 · Reply
ZacksResearch
ZacksResearch Oct. 23 at 4:06 PM
$HALO raises its 2025 outlook — but can partner royalties really power the next leg of growth? Revenue guidance is climbing on strong royalty momentum from Darzalex SC, Phesgo, and Vyvgart Hytrulo — yet dependence on partners still looms large. Full breakdown on what this means for Halozyme’s growth story 👉 https://www.zacks.com/stock/news/2775263/will-higher-royalties-from-partners-fuel-halos-growth-in-h2-2025?cid=sm-stocktwits-2-2775263-teaser-17308&ADID=SYND_STOCKTWITS_TWEET_2_2775263_TEASER_17308
0 · Reply
ZacksResearch
ZacksResearch Oct. 23 at 3:06 PM
$HALO's 37.6% rally YTD — examining its current valuation at this premium. 🚀 🔍 Revenue growth fueled by strong royalties from J&J's Darzalex SC, Roche's Phesgo, and argenx’s Vyvgart Hytrulo. 📈 EPS estimates for 2025 & 2026 are on the rise, but the stock trades at a pricey P/S ratio of 6.93 vs. the industry's 2.28. Discover if HALO's growth justifies its valuation here 👉 https://www.zacks.com/stock/news/2775263/will-higher-royalties-from-partners-fuel-halos-growth-in-h2-2025?cid=sm-stocktwits-2-2775263-body-17294&ADID=SYND_STOCKTWITS_TWEET_2_2775263_BODY_17294
0 · Reply
Sean29md
Sean29md Oct. 22 at 3:08 PM
$HALO markets will sniff out the new Enhanze deal (likely with Gilead). Don’t be surprised if halo share prices rise ahead of the official news. If it is indeed Gilead (based on the patent the two companies filed jointly), expect a minimum of 20-30% gains.
0 · Reply
Sean29md
Sean29md Oct. 21 at 4:23 PM
$HALO $GILD Halozyme's earnings release was supposed to be on 10/28. Now it's been moved back to 11/3 which is after Golead's 10/30 earnings call. Coincidence? The linked (see below) patent (WO2025188901) appears to describe the use of Halozyme's Enhanze drug delivery technology in combination with Trodelvy, which is a breast cancer therapy developed by Gilead[1]. The fact that Halozyme is filing intellectual property specifically covering the pairing of its Enhanze platform with a Gilead molecule strongly suggests ongoing technical collaboration, and is often a precursor to a formal commercial partnership or licensing agreement. The patent in question is a strong signal that Halozyme and Gilead are either in late-stage partnership discussions or at the threshold of a formal deal announcement covering Enhanze-enabled subcutaneous Trodelvy delivery. patentscope.wipo.int/search/en/deta…
0 · Reply
JarvisFlow
JarvisFlow Oct. 20 at 3:35 PM
Morgan Stanley has updated their rating for Halozyme Therapeutics ( $HALO ) to Overweight with a price target of 79.
1 · Reply
Sean29md
Sean29md Oct. 20 at 3:23 PM
$HALO Many thanks to Morgan Stanley for the opportunity to load up more one week ahead of earnings.
1 · Reply
Sean29md
Sean29md Oct. 20 at 2:33 PM
$HALO Many thanks to Morgan Stanley for the opportunity to load up more one week ahead of earnings.
0 · Reply
NoobyDoo
NoobyDoo Oct. 17 at 4:32 PM
$HALO Something big this way comes…Gilead partnership announcement soon? 🤔 I like our chances $HALO
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 3:39 PM
Enter: $HALO NOV 21 2025 $70 CALLS Buy in Price: $2.50 - $2.65 Take Profit: $3.55 Stop Bleeding: $2.20 ROI Potential: 42% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
ZacksResearch
ZacksResearch Oct. 16 at 6:38 PM
$HALO up nearly 40% YTD — is it time to chase or chill? 🧐 The rally’s powered by surging ENHANZE royalties, and the Elektrofi deal adds a solid long-term diversification angle. Full strategy breakdown here 👉 https://www.zacks.com/stock/news/2770532/halozyme-rallies-almost-40-ytd-how-should-you-play-the-stock?cid=sm-stocktwits-2-2770532-teaser-16493&ADID=SYND_STOCKTWITS_TWEET_2_2770532_TEASER_16493
0 · Reply
ZacksResearch
ZacksResearch Oct. 16 at 5:38 PM
$HALO soaring 38.8% as of now — but is it time to hold? 🤔 💊 Strong royalty revenue growth, up 52.3% year over year in the first half of 2025 💼 New Elektrofi deal set to diversify and support long-term growth 📈 2025 revenue guidance up 26-33% over 2024 Discover why HALO might still be a hold amid its rally 👉 https://www.zacks.com/stock/news/2770532/halozyme-rallies-almost-40-ytd-how-should-you-play-the-stock?cid=sm-stocktwits-2-2770532-body-16481&ADID=SYND_STOCKTWITS_TWEET_2_2770532_BODY_16481
0 · Reply
JarvisFlow
JarvisFlow Oct. 15 at 10:32 AM
HC Wainwright & Co. updates rating for Halozyme Therapeutics ( $HALO ) to Buy, target set at 90.
0 · Reply
Sean29md
Sean29md Oct. 15 at 1:12 AM
$HALO Helen today: "Now that drug developers have a better grasp of the IRA’s impact, Halozyme has seen a ramp-up of deal discussions over the last 12 months, and Torley said she’s “very pleased" with the ongoing conversations. “We are going to sign and announce a deal this year, and we’re very excited about that,” the Halozyme CEO said.”
0 · Reply
Sean29md
Sean29md Oct. 15 at 1:06 AM
$HALO Helen's interview with Fierce Pharma https://www.fiercepharma.com/pharma/halozyme-ceo-targets-ma-and-new-deals-ira-uncertainty-pharma-subsides
0 · Reply
notreload_ai
notreload_ai Oct. 14 at 6:36 PM
Leerink upgrades $HALO to Market Perform after company reveals only 20% of ENHANZE sales come from Medicare Part B, significantly less than feared. Price target remains $70. https://notreload.xyz/halozyme-upgraded-medicare-fears-ease/
0 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 6:22 PM
Leerink Partners updates rating for Halozyme Therapeutics ( $HALO ) to Market Perform, target set at 70.
0 · Reply
Sean29md
Sean29md Oct. 14 at 1:47 PM
$HALO Johnson & Johnson’s Darzalex (daratumumab) sales for Q3 2025 exceeded market estimates. Worldwide net sales reached $3.672 billion, surpassing the consensus analyst forecast
0 · Reply
Sean29md
Sean29md Oct. 14 at 1:14 PM
$HALO Halozyme’s position statement on CMS Final IPAY 2028 Guidance. https://www.sec.gov/Archives/edgar/data/1159036/000115903625000039/halozymestatementoncmsfi.htm
0 · Reply
Sean29md
Sean29md Oct. 13 at 3:07 AM
$HALO Forecast of halozyme price action with Gilead Enhanze partnership https://chatgpt.com/s/t_68ec65b25c088191b3e2c72a99d24886 https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025188901
0 · Reply
Sean29md
Sean29md Oct. 11 at 6:53 PM
$HALO halozyme compared to S&P 500
0 · Reply
Sean29md
Sean29md Oct. 11 at 4:14 PM
$HALO 2025 PE ratio estimate is now with a 10 handle (10.9, see link below). I think this is the lowest current full calendar year estimated PE halozyme has ever traded at since it became profitable 5 years ago. The 2024 PE ratio is 16. This means that for halo to maintain the same PE ratio in 2025 as 2024, by the end of 4th quarter 2025 (let's say Feb 2026 when halozyme releases the 4th quarter earnings) PE has to go from 10 to 16. That is a 60% appreciation in shareprice and this would not even factor in the increase in earnings quarter over quarter. In other words, even with the same valuations and assuming zero increase in earnings (which we know will not be the case), halozyme is due for massive run up. 60% increase, would take it to $102. And the amazing thing about that share price is that it will represent a PE of only 16; still be a bargain for a +70% profit margin company with +25% EPS CAGR. https://www.nasdaq.com/market-activity/stocks/halo/price-earnings-peg-ratios
0 · Reply